MedTrace Logo

Rosuvastatin and Evolocumab for Coronary Artery Disease

NCT05984953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 195

Last updated 2023-08-09

No results posted yet for this study

Summary

The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the catheterization laboratory during the following time-period: 8/1/2013-4/14/2015 and 5/4/2021 - 10/28/2022.

Conditions

Interventions

DRUG

statin

40 mg of rosuvastatin daily for 8-12 weeks

DRUG

evolocumab

140 mg evolocumab every 2 weeks (26 weeks)

Sponsors & Collaborators

Principal Investigators

  • Annapoorna Kini, MD · MOUNT SINAI HOSPITAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-01
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05984953 on ClinicalTrials.gov